Abstract:HIV-1 based lentiviral viruses are considered powerful and versatile gene therapy vectors to deliver therapeutic genes to patients with hereditary or acquired diseases. These vectors can efficiently transduce a variety of cell types when dividing or non-dividing to provide permanent delivery and long-term gene expression. Demand for scalable manufacturing protocols able to generate enough high titre vector for widespread use of this technology is increasing and considerable efforts to improve vector production cost-effectively, is ongoing. Current methods for LV production mainly use transient transfection of producer cell lines. Cells can be grown at scale, either in 2D relying on culturing producer cells in multi-tray flask cell culture factories or in roller bottles or can be adapted to grow in 3D suspensions in large batch fermenters. This suits rapid production and testing of new vector constructs pre-clinically for their efficacy, particle titre and safety. In this study, we sought to improve lentiviral titre over time by testing two alternative commercially available transfection reagents Fugene® 6 and Genejuice® with the commonly used polycation, polyethyleneimine. Our aim was to identify less cytotoxic transfection reagents that could be used to generate LV particles at high titre past the often used 72 hour period when vector is usually collected before producer cell death is caused due to post transfection cytotoxicity. We show that LV could be produced in extended culture using Genejuice® and even by transfected cells in glass flasks in suspension. Because this delivery agent is less toxic to 293T producer cells, following optimisation of transfection we found that LV can be harvested for more than 10 days at high titre. Using our protocol, titres of 10 9 TU/ml and 10 8 TU/ml were routinely reached via traditional monolayer conditions or suspension cultures, respectively. We propose, this simple change in vector production enables large volumes of high titre vector to be produced, cost effectively for non-clinical in vivo and in vitro applications or for more stringent downstream clinical grade vector purification.

Optimization of Production Procedure of Replicating Recombinant Live Vaccinia Virus Vector-based Vaccine

Chronological Management of Adjuvant Effect for Optimized Mrna Vaccine Inspired by Natural Virus Infection.

Process Optimization for the Rapid Production of Adenoviral Vectors for Clinical Trials in a Disposable Bioreactor System.

Rapid Titration of Recombinant Baculoviruses Based on NanoLuc Secretion in Early Infection.

The efficient development of a novel recombinant adenovirus zoster vaccine perfusion production process

Optimization of Culture Media and Feeding Strategy for High Titer Production of an Adenoviral Vector in HEK 293 Fed-Batch Culture

High‐yield recombinant adeno‐associated viral vector production by multivariate optimization of bioprocess and transfection conditions

Process Improvement of Adeno-Associated Virus Production

Optimization of Virus Yield as a Strategy to Increase the Efficiency of Rabies Vaccine by BHK-21 Cells in a Bioreactor

Expression, Purification, and Renaturation of a Recombinant Peptide-Based HIV Vaccine in Escherichia Coli.

Process optimization for the rapid production of Enterovirus 71

Optimization of packaging the HIV-1 pseudotyped virus

Optimised protocols to generate high titre lentiviral vectors using a novel transfection agent enabling extended HEK293T culture following transient transfection and suspension culture

FERMENTATION PREPARATION OF RECOMBINANT Vibrio anguillarum VACCINE WITH HETEROGENEOUS ANTIGEN DISPLAY

Development of an HSV-1 production process involving serum-reduced culturing and bead-to-bead transfer

Generation of Recombinant Vaccinia Viruses Via Green Fluorescent Protein Selection

Enhancing the production of recombinant adeno-associated virus in synthetic cell lines through systematic characterization

Process Design and Optimization towards Digital Twins for HIV-Gag VLP Production in HEK293 Cells, including Purification

Optimization of fermentation conditions for an Escherichia coli strain engineered using the response surface method to produce a novel therapeutic DNA vaccine for rheumatoid arthritis

Parallel Multifactorial Process Optimization and Intensification for High-Yield Production of Live YF17D-Vectored Zika Vaccine

Pseudorabies virus production using a serum-free medium in fixed-bed bioreactors with low cell inoculum density